Free Trial
OTCMKTS:HYPMY

Hypera (HYPMY) Stock Price, News & Analysis

Hypera logo
$3.46 0.00 (0.00%)
(As of 11/21/2024 ET)

About Hypera Stock (OTCMKTS:HYPMY)

Key Stats

Today's Range
$3.41
$3.46
50-Day Range
$3.36
$5.33
52-Week Range
$3.31
$7.90
Volume
62,478 shs
Average Volume
82,311 shs
Market Capitalization
$2.19 billion
P/E Ratio
6.49
Dividend Yield
4.34%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

Receive HYPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hypera and its competitors with MarketBeat's FREE daily newsletter.

HYPMY Stock News Headlines

Hypera S.A. Reports Strategic Shift Amid Revenue Decline
Let’s be blunt
Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!
EMS offers to buy Hypera for R$30 per share, Brazil Journal reports
Hypera confirms acquisition proposal received from EMS
See More Headlines

HYPMY Stock Analysis - Frequently Asked Questions

Hypera's stock was trading at $7.16 at the start of the year. Since then, HYPMY shares have decreased by 51.7% and is now trading at $3.46.
View the best growth stocks for 2024 here
.

Shares of HYPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:HYPMY
Fax
N/A
Employees
10,783
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.59 billion
Cash Flow
$0.57 per share
Book Value
$3.26 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.19 billion
Optionable
Not Optionable
Beta
1.06
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (OTCMKTS:HYPMY) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners